SAN DIEGO, May 20, 2013 /PRNewswire/ --Volcano Corporation (VOLC) a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced it will highlight its efforts to expand research and innovation surrounding its physiology technologies, including its Fractional Flow Reserve (FFR) and iFR (Instant Wave-Free Ratio)1 technologies, via various clinical and educational presentations and events at EuroPCR 2013 in Paris.

"Volcano is committed to making clinical and technological advances that expand access to functional management," commented Michele Perrino, president of Europe, Middle East, Africa, and India Operations of Volcano. "Our focus at EuroPCR is to introduce our latest functional management technologies and clinical data, and demonstrate their potential to improve both patient care and the experience for our physician partners in Europe. Given our commitment to provide physicians with choice, we are excited to feature iFR, our novel hyperemia-free software modality, and our Verrata Pressure Guide Wire, which upon regulatory clearance will be our fifth new guide wire in five years."2

Volcano will formally launch its iFR modality and CORE Integrated System, and display the Verrata Wire at the conference. Volcano will showcase its future and currently available physiology, imaging, and multi-modality systems products in the company's exhibit hall booth #M71.

Featured events for Volcano include four live case symposia demonstrating the benefits of incorporating both FFR and our iFR modality in simple and complex cases, the presentation of the findings from the Adenosine Vasodilator Independent Stenosis Evaluation II (ADVISE II) study data at a hot line session, and over 10 scientific podium presentations featuring advanced physiology using Volcano products.

Key EventsWednesday, May 22, 10:50 11:30 a.m. Complex bifurcation stenting: LIVE demonstration of emerging techniquesLIVE iFR demonstration from Erasmus University Medical Center, Thorax Center Rotterdam, The Netherlands Theatre Bleu

Thursday, May 23, 9:45 - 11:45 a.m. Adenosine Vasodilator Independent Stenosis Evaluation II (ADVISE II)Hot Line - Evolving procedural strategies Room 351

Thursday, May 23, 4:45 6:45 p.m. Physiological Stenosis Assessment with FFR and Instant Wave-Free Ratio: We Need Both!Live case demonstrations (simple and multivessel disease) from St. Thomas' Hospital, London, followed by panel discussions Theatre Bordeaux

Friday, May 24, 9:00 12:30 p.m. Complex cardiovascular interventions and new techniques Master LIVE demonstrations Continuous LIVE FFR and iFR demonstrations from Sunninghill and Sunward Park Hospitals, South Africa and St Thomas' Hospital London, United Kingdom Main Arena

Daily, 12:00 3:00 p.m. Meet the iFR Experts Booth #M71

About Volcano Corporation Volcano Corporation is revolutionizing the medical device industry with a broad suite of technologies that make imaging and therapy simpler, more informative and less invasive. Its products empower physicians around the world with a new generation of analytical tools that deliver more meaningful information - using sound and light as the guiding elements. Founded in cardiovascular care and expanding into other specialties, Volcano is changing the assumption about what is possible in improving patient outcomes by combining imaging and therapy together.

See more here:
Volcano to Highlight its Physiology Expansion Efforts at EuroPCR 2013